13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • ACED

    Acronym: 

    ACED

    ACTRN/NCT /ethics: 

    ACTRN12615001072505

    Scientific title: 

    A Phase II randomised placebo-controlled, double blind, multisite study of Acetazolamide versus placebo for management of cerebral oedema in recurrent and/or progressive High Grade Glioma requiring treatment with Dexamethasone.

    Summary of trial and patient characteristics

    Cancer Type Brain & central nervous system
    Trial Type Treatment
    Phase Phase II Tumour Stream Brain
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced
    Sex Both Anticipated Start Date 2016-07-19
    Molecular Target Anticipated End Date
    Cancer Type Brain & central nervous system
    Trial Type Treatment
    Phase Phase II
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Brain
    Cancer Stage Locally Recurrent or Locally Advanced
    Anticipated Start Date 2016-07-19
    Anticipated End Date

    Trial Summary

    This study investigates whether addition of the drug acetazolamide to a dexamethasone treatment for controlling raised intracranial pressure symptoms, related to high grade glioma brain tumour (such as headache, nausea and vomiting), will allow the dexamethasone dosage to be reduced, and whether this leads to less dexamethasone-related side-effects.

    Lay Summary

    A Phase II randomised placebo-controlled, double blind, multisite study of Acetazolamide versus placebo for management of cerebral oedema in recurrent and/or progressive High Grade Glioma requiring treatment with Dexamethasone.

    Sponsor / Cooperative group

    The University of Sydney

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Flinders Medical Centre Alex Scott-Hoy alex.scott-hoy@sa.gov.au 08 8204 4830 Ganessan Kichenadasse Recruiting